Abstract:Abstract Background RBM10 is frequently mutated in lung adenocarcinoma (LUAD). Several studies identified RBM10 could regulate proliferation and apoptosis, but how can RBM10 mutations affect tumor microenvironment (TME) is elusive. We aimed to explore the effect of RBM10 mutations on TME. Methods Whole-exome sequencing (WES) was performed on 39 treatment-naïve early-stage LUADs presenting as ground-glass nodules (GGN). Data from TCGA database (n=562) and WES and RNA-sequencing (RNA-seq) data of another Chinese LUAD cohort (n=128, CHOICE_ADC cohort) were obtained. GSEA was performed to determine immune related pathways. Single-sample GSEA (ssGSEA), CIBERSORT and TIMER were used to evaluate immune infiltration. TIDE was used to calculate the predictive immunotherapy response. Results RBM10 mutational frequency in TCGA and CHOICE_ADC cohort were 7% and 8%, but reached 28% in GGN cohort. Because there were more early-stage LUADs in our cohort, RBM10 more likely mutated in early-stage LUAD. Additionally, majority of RBM10 mutations were protein-truncating variants, including nonsense and frameshift mutation. Survival analysis revealed RBM10 deficiency was related to shorter overall survival. GSEA was performed using RNA-seq data from TCGA and CHIOCE_ADC cohort and revealed immune related pathways were enriched in RBM10 deficient population. In TCGA cohort, the inflammatory response and TGF-β signaling were two of the representative enriched pathways. Similarly, the interferon-γ response and TNF-α signaling via NF-κB were two of the most enriched pathways in CHOICE_ADC cohort. The number of neoantigen and tumor mutation burden were higher in patients with RBM10 mutations. We further compared HLA expression between patients with RBM 10 mutations and wild-type population and found numerous HLAs showed higher expression in RBM10 deficient population, such as HLA.DRB6, HLA.DRB5 and HLA.DQA1. By using ssGSEA, we found diverse immune signatures (Th1 cells, macrophages, DC and CD8+T cells) showed higher enrichment levels in population with low RBM10 expression in both TCGA and CHOICE_ADC cohort. Similarly, RBM10 expression had a positive correlation with the levels of myeloid dendritic cell, macrophage, neutrophil, CD8+T cell and CD4+T cell according to the results of TIMMER and CIBERSORT. Finally, we found PD-L1 and TIM3 exhibited higher expression in population with RBM10 deficiency. Additionally, the predicted immunotherapy response was calculated through TIDE algorithm. Expression of IFNG was upregulated and immune evasion level was lower in population with RBM10 deficiency. Conclusion RBM10 mutations were more common in early-stage LUADs. Immune activity in patients with RBM10 mutations was elevated and there were more neoantigens in these patients. Our results demonstrated that LUAD patients with RBM10 mutations could more likely benefit from immunotherapy. Citation Format: Bing Liu, Yang Chen, Nan Wu. RBM10 mutations remodel tumor microenvironment of lung adenocarcinoma and contribute to its progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2822.

Abstract 3999: Experimental study of tumor suppressor gene RBM5 in non-small cell lung cancer

The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis

RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer:

Tumor suppressor gene RBM5 delivered by attenuated Salmonella inhibits lung adenocarcinoma through diverse apoptotic signaling pathways

Differential Expression of RBM5, EGFR and KRAS Mrna and Protein in Non-Small Cell Lung Cancer Tissues.

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.

3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

Lentiviral Vector-Mediated RBM5 Overexpression Downregulates EGFR Expression in Human Non-Small Cell Lung Cancer Cells

Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)

Expressions of RBM5, EGFR and KRAS and their significance in patients with non-small cell lung cancer

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma

RBM5 Inhibits Tumorigenesis of Gliomas Through Inhibition of Wnt/β-catenin Signaling and Induction of Apoptosis

Abstract 2822: RBM10 Mutations Remodel Tumor Microenvironment of Lung Adenocarcinoma and Contribute to Its Progression

RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cells via stabilizing phosphatase and tensin homolog mRNA

Abstract #5347: the Lung Tumor Suppressor GPRC5A Inhibits Activation of NF-\#954;B in Human Non-Small Cell Lung Adenocarcinoma Cells

RBM5 Acts As Tumor Suppressor in Medulloblastoma Through Regulating Wnt/β-Catenin Signaling

Rbm10 Mutations Remodel Tumor Microenvironment Of Lung Adenocarcinoma And Contribute To Its Progression.